FDA advises stopping SGLT2 inhibitor treatment prior to surgery
The changes affect canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, and were made because surgery may put patients taking SGLT2...
Treating COVID-19 in patients with diabetes
Most health advisories about COVID-2019 mention diabetes as one of the high-risk categories for the disease.
COVID-19: Extra caution needed for patients with diabetes
Coexisting heart disease, kidney disease, advanced age, and frailty are likely to further increase the severity of disease.
MACE benefits with dapagliflozin improve with disease duration
Findings suggest treatment with the SGLT-2 inhibitor should be initiated early in some high-risk patients.
Can this patient get IV contrast?
Patients with seafood allergy have a higher rate of reactions to iodinated contrast, but not at a higher rate than patients with other food...
Noninjectable modes of insulin delivery coming of age
Treatment of heart failure with preserved ejection fraction is a work in progress
Although the disorder has a lower mortality than heart failure with reduced ejection fraction, it places a significant burden on health care...
Farxiga granted Priority Review for treatment of adults with HFrEF
The Food and Drug Administration is reviewing dapagliflozin for reducing the risk of cardiovascular death or worsening of heart failure in adults...
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib.
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.